SCHEMBL23923707

SCHEMBL23923707

C/C=C/c1cccc(O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
CA12 O43570 4/20 0.42
CA1 P00915 4/20 0.42
CA9 Q16790 4/20 0.42
RELA Q04206 1/20 0.40
NFE2L2 Q16236 3/20 0.38
CYP19A1 P11511 1/20 0.37
NQO2 P16083 1/20 0.37
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36
TUBB8 Q3ZCM7 1/20 0.36
TUBA3E Q6PEY2 1/20 0.36
TUBA1A Q71U36 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923708 1.00 HSP90AA1 (0.52) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL6158612 0.84 HSP90AA1 (0.50) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL20573442 0.83 HSP90AA1 (0.52) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL1162277 0.83 HSP90AA1 (0.49) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL413810 0.82 HSP90AA1 (0.47) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL1010834 0.82 HSP90AA1 (0.50) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL17513850 0.81 HSP90AA1 (0.61) HSP90AA1HSP90AB1CYP1A1CYP1A2CYP1B1
SCHEMBL17513851 0.81 HSP90AA1 (0.61) HSP90AA1HSP90AB1CYP1A1CYP1A2CYP1B1
SCHEMBL7706827 0.80 CA1 (0.50) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL17529414 0.80 HSP90AA1 (0.60) HSP90AA1HSP90AB1CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010912-A Antiviral 1, 3-dioxoindene compounds 诺华股份有限公司 2026-05-12 CN disclosed
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-06-12 US disclosed
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2025-04-29 US disclosed
CN-115867545-A Antiviral 1,3 dioxoindene compounds 诺华股份有限公司 2023-03-28 CN disclosed
EP-4139301-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS Novartis AG (CH) 2023-03-01 EP disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 WO disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 HSP90AA1 3749/4885HSP90AB1 3232/4885CA12 3305/4885
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 HSP90AA1 3749/4885HSP90AB1 3232/4885CA12 3305/4885
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, ZC3HAV1 HSP90AA1 3749/4885HSP90AB1 3232/4885CA12 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.